SG11202108927UA - Substituted pyrrolopyridines as jak inhibitors - Google Patents

Substituted pyrrolopyridines as jak inhibitors

Info

Publication number
SG11202108927UA
SG11202108927UA SG11202108927UA SG11202108927UA SG11202108927UA SG 11202108927U A SG11202108927U A SG 11202108927UA SG 11202108927U A SG11202108927U A SG 11202108927UA SG 11202108927U A SG11202108927U A SG 11202108927UA SG 11202108927U A SG11202108927U A SG 11202108927UA
Authority
SG
Singapore
Prior art keywords
jak inhibitors
substituted pyrrolopyridines
pyrrolopyridines
substituted
jak
Prior art date
Application number
SG11202108927UA
Inventor
Eric Jon Jacobsen
David Randolph Anderson
James Robert Blinn
Paramita Mukherjee
Paul CHANGELIAN
Canxin Xu
Original Assignee
Aclaris Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aclaris Therapeutics Inc filed Critical Aclaris Therapeutics Inc
Publication of SG11202108927UA publication Critical patent/SG11202108927UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG11202108927UA 2019-05-02 2020-05-04 Substituted pyrrolopyridines as jak inhibitors SG11202108927UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962842197P 2019-05-02 2019-05-02
PCT/US2020/031332 WO2020223728A1 (en) 2019-05-02 2020-05-04 Substituted pyrrolopyridines as jak inhibitors

Publications (1)

Publication Number Publication Date
SG11202108927UA true SG11202108927UA (en) 2021-09-29

Family

ID=73017367

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108927UA SG11202108927UA (en) 2019-05-02 2020-05-04 Substituted pyrrolopyridines as jak inhibitors

Country Status (12)

Country Link
US (2) US11420966B2 (en)
EP (1) EP3962897A4 (en)
JP (1) JP2022531088A (en)
KR (1) KR20220004726A (en)
CN (1) CN113727975A (en)
AU (1) AU2020265828A1 (en)
CA (1) CA3138544A1 (en)
IL (1) IL287717A (en)
MX (1) MX2021013224A (en)
SG (1) SG11202108927UA (en)
WO (1) WO2020223728A1 (en)
ZA (1) ZA202105837B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3081751A1 (en) 2017-11-03 2019-05-09 Aclaris Therapeutics, Inc. Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
SG11202100525SA (en) 2018-08-10 2021-02-25 Aclaris Therapeutics Inc Pyrrolopyrimidine itk inhibitors
WO2021067626A2 (en) 2019-10-01 2021-04-08 Intima Bioscience, Inc. Genetic engineering of fungi to modulate tryptamine expression
CN113200983B (en) * 2021-05-22 2023-01-03 中国药科大学 Compound with pyrrolopyridine structure, preparation method and medical application

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10075033I2 (en) 1993-11-30 2001-08-02 Searle & Co substituted pyrazolyl-benzenesulfonamides for the treatment of inflammation.
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
CA2337999A1 (en) 1998-06-30 2000-01-06 Parker Hughes Institute Method for inhibiting c-jun expression using jak-3 inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
SE0301372D0 (en) 2003-05-09 2003-05-09 Astrazeneca Ab Novel compounds
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
RU2435769C2 (en) 2005-05-20 2011-12-10 Вертекс Фармасьютикалз Инкорпорейтед Pyrrolopyridines effective as proteinkinase inhibitors
JP5071374B2 (en) 2005-07-14 2012-11-14 アステラス製薬株式会社 Heterocyclic Janus Kinase 3 Inhibitor
CN102127078A (en) 2005-07-14 2011-07-20 安斯泰来制药株式会社 Heterocyclic janus kinase 3 inhibitors
EP2348023B9 (en) 2005-12-13 2017-03-08 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
US20100105661A1 (en) * 2007-01-12 2010-04-29 Astellas Pharma Inc. Condensed pyridine compound
CN101932582B (en) 2007-06-13 2013-09-25 因塞特公司 Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CL2009001884A1 (en) 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
CN102458581B (en) 2009-05-22 2016-03-30 因塞特控股公司 As pyrazoles-4-base-pyrrolo-[2,3-d] pyrimidine of JANUS kinase inhibitor and N-(mixing) the aryl-pyrrolidine derivative of pyrroles-3-base-pyrrolo-[2,3-d] pyrimidine
WO2012058645A1 (en) * 2010-10-29 2012-05-03 Biogen Idec Ma Inc. Heterocyclic tyrosine kinase inhibitors
EP2640723A1 (en) 2010-11-19 2013-09-25 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
CN105001226B (en) 2011-08-12 2017-09-08 日产化学工业株式会社 Tricyclic heterocyclic compounds and JAK inhibitor
ES2654051T3 (en) 2013-12-05 2018-02-12 Pfizer Inc. Pyrrolo [2,3-d] pyrimidinyl, pyrrolo [2,3-b] pyrazinyl and pyrrolo [2,3-d] pyridinyl acrylamides
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
MD20160121A2 (en) 2014-05-14 2017-05-31 Pfizer Inc. Pyrazolopyridines and pyrazolopyrimidines
EP3360878B9 (en) 2015-12-11 2021-05-05 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
RU2019108280A (en) 2016-08-24 2020-09-25 Аркьюл, Инк. AMINOPYRROLOPYRIMIDINONE COMPOUNDS AND METHODS FOR THEIR APPLICATION
US10800775B2 (en) 2017-11-03 2020-10-13 Aclaris Therapeutics, Inc. Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same
CA3081751A1 (en) 2017-11-03 2019-05-09 Aclaris Therapeutics, Inc. Substituted pyrrolopyrimidine jak inhibitors and methods of making and using the same
SG11202100525SA (en) 2018-08-10 2021-02-25 Aclaris Therapeutics Inc Pyrrolopyrimidine itk inhibitors

Also Published As

Publication number Publication date
US20200347053A1 (en) 2020-11-05
CA3138544A1 (en) 2020-11-05
US11420966B2 (en) 2022-08-23
US20220372034A1 (en) 2022-11-24
EP3962897A1 (en) 2022-03-09
CN113727975A (en) 2021-11-30
KR20220004726A (en) 2022-01-11
EP3962897A4 (en) 2022-12-14
WO2020223728A1 (en) 2020-11-05
IL287717A (en) 2021-12-01
ZA202105837B (en) 2022-07-27
MX2021013224A (en) 2022-01-06
AU2020265828A1 (en) 2021-09-09
JP2022531088A (en) 2022-07-06

Similar Documents

Publication Publication Date Title
IL276677B (en) Naphthyridine compounds as jak kinase inhibitors
EP3248980A4 (en) Jak inhibitor
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
EP3290418A4 (en) Jak inhibitors
IL287717A (en) Substituted pyrrolopyridines as jak inhibitors
EP4067359A4 (en) Pyrimidoimidazole compounds used as dna-pk inhibitors
IL287876A (en) Jak inhibitors
EP3768272A4 (en) Jak inhibitors
EP3844166C0 (en) Substituted macrocycles useful as kinase inhibitors
IL290381A (en) Jak inhibitors
PL3484875T3 (en) Pyrazolylaminobenzimidazole derivatives as jak inhibitors
ZA202101092B (en) Pyridopyrimidines as histamine h4-receptor inhibitors
IL291611A (en) Jak inhibitors
IL292093A (en) Thienopyrimidones as trpa1 inhibitors
IL292095A (en) Thienopyrimidones as trpa1 inhibitors
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors